Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05281471Phase 3Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Role: lead

NCT07136285Phase 1Recruiting

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Role: collaborator

NCT06463665Phase 2Recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Role: lead

NCT01766739Phase 1Completed

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Role: collaborator

NCT03420430Unknown

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

Role: lead

NCT02714374Phase 1Terminated

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Role: collaborator

NCT02759588Phase 1Completed

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Role: lead

NCT01584284Phase 1Completed

Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer

Role: lead

All 8 trials loaded